BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38225722)

  • 1. RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells.
    Hsu SH; Tsai YL; Wang YT; Shen CH; Hung YH; Chen LT; Hung WC
    Adv Sci (Weinh); 2024 Mar; 11(12):e2304820. PubMed ID: 38225722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
    Jiang X; Hao HX; Growney JD; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh MH; Bagdasarian L; Meyer R; Smith TR; Avello M; Charlat O; Xie Y; Porter JA; Pan S; Liu J; McLaughlin ME; Cong F
    Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12649-54. PubMed ID: 23847203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
    Neumeyer V; Grandl M; Dietl A; Brutau-Abia A; Allgäuer M; Kalali B; Zhang Y; Pan KF; Steiger K; Vieth M; Anton M; Mejías-Luque R; Gerhard M
    Carcinogenesis; 2019 Jun; 40(4):551-559. PubMed ID: 30380024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
    Tu J; Park S; Yu W; Zhang S; Wu L; Carmon K; Liu QJ
    Sci Rep; 2019 Dec; 9(1):18557. PubMed ID: 31811196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
    Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
    Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.
    Radaszkiewicz T; Nosková M; Gömöryová K; Vondálová Blanářová O; Radaszkiewicz KA; Picková M; Víchová R; Gybeľ T; Kaiser K; Demková L; Kučerová L; Bárta T; Potěšil D; Zdráhal Z; Souček K; Bryja V
    Elife; 2021 Oct; 10():. PubMed ID: 34702444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNF43 R117fs mutant positively regulates Wnt/β-catenin signaling by failing to internalize FZD expressed on the cell surface.
    Cho AR; Sul HJ; Kim YJ; Kim B; Zang DY
    Sci Rep; 2022 Apr; 12(1):7013. PubMed ID: 35487932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Role of RNF43 in Canonical and Noncanonical Wnt Signaling.
    Tsukiyama T; Fukui A; Terai S; Fujioka Y; Shinada K; Takahashi H; Yamaguchi TP; Ohba Y; Hatakeyama S
    Mol Cell Biol; 2015 Jun; 35(11):2007-23. PubMed ID: 25825523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rnf43.
    Serra S; Chetty R
    J Clin Pathol; 2018 Jan; 71(1):1-6. PubMed ID: 29018044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases.
    Jiang X; Charlat O; Zamponi R; Yang Y; Cong F
    Mol Cell; 2015 May; 58(3):522-33. PubMed ID: 25891077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
    Zhang Y; Sun L; Gao X; Guo A; Diao Y; Zhao Y
    BMC Cancer; 2019 Jul; 19(1):670. PubMed ID: 31286874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
    Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
    Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
    Tsukiyama T; Zou J; Kim J; Ogamino S; Shino Y; Masuda T; Merenda A; Matsumoto M; Fujioka Y; Hirose T; Terai S; Takahashi H; Ishitani T; Nakayama KI; Ohba Y; Koo BK; Hatakeyama S
    Nat Commun; 2020 Sep; 11(1):4586. PubMed ID: 32934222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition.
    Yu J; Yusoff PAM; Woutersen DTJ; Goh P; Harmston N; Smits R; Epstein DM; Virshup DM; Madan B
    Cancer Res; 2020 Dec; 80(24):5619-5632. PubMed ID: 33067269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease associated domain of RNF43 is not necessary for the suppression of Wnt/β-catenin signaling in human cells.
    Radaszkiewicz T; Bryja V
    Cell Commun Signal; 2020 Jun; 18(1):91. PubMed ID: 32527265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).
    Hong SW; Jin DH; Shin JS; Moon JH; Na YS; Jung KA; Kim SM; Kim JC; Kim KP; Hong YS; Lee JL; Choi EK; Lee JS; Kim TW
    J Biol Chem; 2012 Jul; 287(28):24017-25. PubMed ID: 22628551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ZNRF3/RNF43 Unleashes EGFR in Cancer.
    Yue F; Ku AT; Stevens PD; Michalski MN; Jiang W; Tu J; Shi Z; Dou Y; Wang Y; Feng XH; Hostetter G; Wu X; Huang S; Shroyer NF; Zhang B; Williams BO; Liu Q; Lin X; Li Y
    bioRxiv; 2024 Jan; ():. PubMed ID: 38260423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
    Adamopoulos C; Cave DD; Papavassiliou AG
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors.
    Yuan X; Tang Z; Du R; Yao Z; Cheung SH; Zhang X; Wei J; Zhao Y; Du Y; Liu Y; Hu X; Gong W; Liu Y; Gao Y; Huang Z; Cao Z; Wei M; Zhou C; Wang L; Rosen N; Smith PD; Luo L
    Mol Oncol; 2020 Aug; 14(8):1833-1849. PubMed ID: 32336014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.